DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review process, receiving no requests for additional data but valuable feedback on data presentation. DBV plans to incorporate FDA comments and submit the BLA in the third quarter of 2026. This step is crucial for potentially bringing a novel allergy treatment to market, addressing significant unmet medical needs in food allergy management.
Bron, a self-custody crypto wallet provider, has partnered with Noah, a global stablecoin payments infrastructure company, to enable seamless on- and off-ramp access for stablecoins. This integration allows Bron users to easily fund and withdraw from...
YMCA of Northern Alberta and Capital Power have teamed up to send 600 children to summer camp who otherwise could not afford it. Capital Power's three-year commitment supports access to various YMCA camps and programs that build confidence and commun...
Fidelity Advisor Series VIII has increased its voting rights in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% voting rights attached to shares and 0.19% through stock loan instruments. The total voting rights represent a significant...
Fidelity Advisor Series VIII, based in Boston, has raised its voting rights stake in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% direct voting rights and 0.19% through stock loan instruments. The total voting rights are based on 1...
CRCAM Toulouse announced that no repurchases of its cooperative investment certificates (CCI) were made during the week of June 22 to June 26, 2026. This update is part of their regular weekly disclosure on CCI transactions, reflecting no activity in...
